Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6271 to 6285 of 8931 results

  1. Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical practice would be useful to determine the size of the effect of mifamurtide.

    Recommendation ID TA235/1 Question Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical

  2. Behavioural strategies and programmes:- What is the feasibility and effectiveness of specific behavioural strategies and programmes to reduce inappropriate antimicrobial demand and use and to prevent infections occurring and spreading?

    Recommendation ID NG63/2 Question Behavioural strategies and programmes:- What is the feasibility and effectiveness of specific behavioural

  3. Cost effectiveness:- What is the cost effectiveness of interventions to prevent infection and promote the appropriate use of antimicrobials?

    Recommendation ID NG63/1 Question Cost effectiveness:- What is the cost effectiveness of interventions to prevent infection and promote

  4. Older people in day and residential care:- How effective are interventions in day and residential care for older people that aim to prevent infection and to reduce antimicrobial resistance?

    Recommendation ID NG63/5 Question Older people in day and residential care:- How effective are interventions in day and residential care

  5. Workplace:- How effective are interventions in the workplace that aim to prevent infection and reduce antimicrobial resistance?

    Recommendation ID NG63/4 Question Workplace:- How effective are interventions in the workplace that aim to prevent infection and reduce

  6. Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification when selecting which people with CUADT would benefit from short- or long-term enteral nutrition?

    Recommendation ID NG36/4 Question Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification

  7. Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and pathological factors?

    Recommendation ID NG36/3 Question Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary

  8. Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having metastasis or a second primary cancer?

    Recommendation ID NG36/1 Question Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having

  9. Follow-up:- What is the optimal method, frequency and duration of follow-up for people who are disease-free after treatment for CUADT?

    Recommendation ID NG36/5 Question Follow-up:- What is the optimal method, frequency and duration of follow-up for people who are disease-free

  10. HPV testing:- What is the comparative effectiveness of single-step laboratory diagnostic tests to identify human papillomavirus (HPV) against current diagnostic test algorithms and reference standards in people with cancer of the oropharynx?

    Recommendation ID NG36/2 Question HPV testing:- What is the comparative effectiveness of single-step laboratory diagnostic tests to identify

  11. Novel endovascular interventions: What is the clinical and cost effectiveness of novel endovascular techniques and devices such as coated coils, endoluminal flow diverters and intrasaccular devices to treat aneurysmal subarachnoid haemorrhage?

    Recommendation ID NG228/04 Question Novel endovascular interventions: What is the clinical and cost effectiveness of novel endovascular

  12. Follow-up strategies: What is the clinical and cost effectiveness of patient-initiated follow-up compared with routine follow-up for people with osteoarthritis?

    Recommendation ID NG226/04 Question Follow-up strategies: What is the clinical and cost effectiveness of patient-initiated follow-up compared

  13. Oxygen therapy for OSAHS: What is the clinical and cost effectiveness of nocturnal oxygen compared with placebo in people with OSAHS who are unable to tolerate CPAP?

    Recommendation ID NG202/9 Question Oxygen therapy for OSAHS: What is the clinical and cost effectiveness of nocturnal oxygen compared with

  14. What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and young people considered to be at high risk of developing psychosis?

    Recommendation ID CG155/2 Question What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and